Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Cash Flow: 2020-2025

Historic Net Cash Flow for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $25.8 million.

  • SAB Biotherapeutics' Net Cash Flow rose 417.41% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 204.76%. This contributed to the annual value of -$47.4 million for FY2024, which is 214.28% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Net Cash Flow stood at $25.8 million, which was up 1,311.25% from -$2.1 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Net Cash Flow registered a high of $54.1 million during Q4 2023, and its lowest value of -$42.5 million during Q1 2024.
  • Its 3-year average for Net Cash Flow is $1.3 million, with a median of -$2.1 million in 2025.
  • Per our database at Business Quant, SAB Biotherapeutics' Net Cash Flow soared by 33,841.08% in 2021 and then crashed by 2,039.29% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Net Cash Flow (Quarterly) stood at $28.8 million in 2021, then slumped by 76.68% to $6.7 million in 2022, then skyrocketed by 706.03% to $54.1 million in 2023, then tumbled by 99.97% to $15,539 in 2024, then soared by 417.41% to $25.8 million in 2025.
  • Its Net Cash Flow stands at $25.8 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$3.3 million for Q1 2025.